Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients

被引:35
作者
De Luis, DA [1 ]
Avello, AG [1 ]
Lasuncion, MA [1 ]
Aller, R [1 ]
De Argila, CM [1 ]
De Miquel, DB [1 ]
De la Calle, H [1 ]
机构
[1] Univ Alcala de Henares, Hosp Ramon y Cajal, Dept Endocrinol, Madrid 28034, Spain
关键词
haemostasis; Helicobacter pylori; lipids;
D O I
10.1016/S0261-5614(99)80074-0
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Helicobacter pylori has been implicated in the cardiovascular risk of diabetic patients. The aim of our study was to investigate whether the Helicobacter pylori Infection plays a role in the lipid and haemostasis patterns of type 1 diabetic patients. Twenty nine patients with type 1 diabetes mellitus and H. pylori Infection were enrolled (Chlamydia pneumoniae negative). The H. pylori infection status was assessed by serology and urease breath test. In all patients levels of total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, lipoprotein (a) (Lpa) C reactive protein (CRP), fibrinogen, thrombin/antithrombin III complex (TAT), plasminogen activator inhibitor type 1(PAI-1), tissue plasminogen activator (t-PA) and von Willebrand antigen were measured. All patients were evaluated before and after H. pylori eradicating treatment with amoxicillin, clarithromycin and omeprazole. Twenty two patients were eradicated and seven remained infected. In H. pylori eradicated patients, HDL cholesterol increased (59.7+/-18.9 mg/dl vs 65.2+/-15.9 mg/dl, P < 0.05) and lipoprotein (a) decreased (23.1+/-14.0 mg/dl vs 18.3+/-12.3 mg/dl, P < 0.05), after treatment. After H. pylori eradication, the levels of CRP and TAT decreased (48+/-0.7 ng/l vs 3.3+/-0.4 ng/l; P < 0.05), (27.7+/-44.7 mu g/ml vs 2.1+/-1.4 mu g/ml P < 0.05), respectively. The decrease in TAT was higher in the group of H. pylori (+) patients with higher levels of TAT (TAT > 20 ng/ml, 92.8+/-41.6 ng/ml vs 1.9+/-2.0 ng/ml, P < 0.005; TAT 4-20 ng/ml; 10.1+/-5.2 ng/ml vs 2.2+/-0.6 ng/ml, P < 0.05). These changes did not occur in patients without H. pylori eradication. Eradication of H. pylori infection in type 1 diabetic patients modifies some parameters of lipid and haemostasis patterns, (increase of HDL-cholesterol, reduction of Lpa and decrease of CRP and TAT) and so contributes to improvement of cardiovascular risk factors in these patients.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 30 条
[1]   DYSLIPOPROTEINEMIA IN PATIENTS WITH SEVERE BACTERIAL-INFECTIONS [J].
AKERLUND, B ;
CARLSON, LA ;
JARSTRAND, C .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1986, 18 (06) :539-545
[2]  
BERGSDORF N, 1983, THROMB HAEMOSTASIS, V50, P740
[3]  
BIERTI L, 1997, GASTROENTEROLOGY, pA90
[4]   Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms [J].
Blasi, F ;
Denti, F ;
Erba, M ;
Cosentini, R ;
Raccanelli, R ;
Rinaldi, A ;
Fagetti, L ;
Esposito, G ;
Ruberti, U ;
Allegra, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (11) :2766-2769
[5]   CLINICAL IMPORTANCE OF CAMPYLOBACTER-PYLORIDIS AND ASSOCIATED SERUM IGG AND IGA ANTIBODY-RESPONSES IN PATIENTS UNDERGOING UPPER GASTROINTESTINAL ENDOSCOPY [J].
BOOTH, L ;
HOLDSTOCK, G ;
MACBRIDE, H ;
HAWTIN, P ;
GIBSON, JR ;
IRELAND, A ;
BAMFORTH, J ;
DUBOULAY, CE ;
LLOYD, RS ;
PEARSON, AD .
JOURNAL OF CLINICAL PATHOLOGY, 1986, 39 (02) :215-219
[6]  
CABANA VG, 1989, J LIPID RES, V30, P39
[7]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[8]   MUCOSAL TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-6 IN PATIENTS WITH HELICOBACTER-PYLORI ASSOCIATED GASTRITIS [J].
CRABTREE, JE ;
SHALLCROSS, TM ;
HEATLEY, RV ;
WYATT, JI .
GUT, 1991, 32 (12) :1473-1477
[9]   Elevated serum lipoprotein(a) levels in young women with endometriosis [J].
Crook, D ;
Howell, R ;
Sidhu, M ;
Edmonds, DK ;
Stevenson, JC .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (07) :735-739
[10]   Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients [J].
de Luis, DA ;
Lahera, M ;
Cantón, R ;
Boixeda, D ;
San Román, AL ;
Aller, R ;
de la Calle, H .
DIABETES CARE, 1998, 21 (07) :1129-1132